introduct
human
host
immun
respons
follow
infect
new
variant
pandem
influenza
viru
poorli
understood
util
system
cytokin
antibodi
level
evalu
differ
earli
immun
respons
mild
sever
patient
infect
method
profil
cytokin
chemokin
evalu
haemagglutin
inhibit
activ
quantit
qualit
measur
host
immun
respons
serum
obtain
first
five
day
symptom
onset
two
cohort
infect
patient
sever
patient
requir
hospit
n
due
respiratori
insuffici
admit
intens
care
unit
mild
patient
exclus
flulik
symptom
n
group
healthi
donor
includ
control
n
differ
level
mediat
group
assess
use
non
parametr
umann
whitney
test
associ
variabl
determin
calcul
spearman
correl
coeffici
viral
load
perform
serum
use
realtim
pcr
target
neuraminidas
gene
result
increas
level
innateimmun
mediat
absenc
antibodi
character
earli
respons
infect
hospit
mild
patient
high
system
level
typeii
interferon
also
group
mediat
involv
develop
thelper
thelper
respons
exclus
found
hospit
patient
constitut
hallmark
critic
ill
studi
signific
invers
associ
found
critic
patient
conclus
infect
induc
typic
innat
respons
mild
sever
patient
sever
diseas
respiratori
involv
character
earli
secret
cytokin
usual
associ
cell
mediat
immun
also
commonli
link
pathogenesi
autoimmuneinflammatori
diseas
exact
role
mediat
evolut
mild
sever
diseas
merit
investig
detriment
benefici
role
cytokin
play
sever
ill
emerg
new
pandem
variant
influenza
viru
brought
renew
attent
strategi
prevent
treatment
minim
social
human
cost
influenza
diseas
great
major
infect
mild
selflimit
natur
nevertheless
small
percentag
patient
requir
hospit
special
attent
intens
care
unit
icu
mani
sever
case
occur
healthi
young
adult
age
group
rare
serious
affect
season
influenza
pregnanc
metabol
condit
includ
obes
diabet
identifi
risk
factor
sever
diseas
fatal
case
document
underli
medic
condit
new
viru
caus
sever
patholog
lesion
lung
infect
mice
ferret
nonhuman
primat
season
human
viru
role
host
immun
respons
clearanc
role
host
immun
respons
contribut
sever
respiratori
pathogenesi
infect
known
time
previous
identifi
specif
host
immun
respons
chemokin
cytokin
signatur
sever
mild
sar
cov
respiratori
syncyti
viru
infect
studi
earli
host
immun
respons
character
express
system
level
chemokin
indic
innat
anti
viral
respons
sever
mild
sar
rsv
ill
could
defin
chemokin
cytokin
signatur
involv
develop
adapt
immun
interestingli
de
jong
et
al
demonstr
hypercytokinemia
specif
chemokin
cytokin
associ
sever
often
fatal
case
human
infect
determin
host
immun
respons
play
potenti
role
evolut
mild
sever
ill
perform
analysi
system
chemokin
cytokin
level
serum
sever
mild
patient
shortli
follow
onset
symptom
interestingli
identifi
cytokin
signatur
uniqu
mild
sever
patient
hospit
outpati
recruit
first
pandem
wave
month
juli
august
differ
hospit
within
nation
public
health
system
spain
inclus
criteria
critic
patient
respiratori
insuffici
hospit
non
critic
patient
respiratori
insuffici
mild
outpati
respiratori
insuffici
attend
particip
center
confirm
infect
molecular
diagnost
method
see
ask
donat
serum
sampl
studi
first
contact
particip
physician
initi
enrol
hospit
patient
outpati
determin
system
level
chemokin
cytokin
sera
infect
individu
analyz
sera
hospit
outpati
control
subject
level
differ
mediat
final
number
patient
use
analysi
base
exclus
match
criteria
list
figur
exclus
criteria
patient
sign
bacteri
infect
defin
presenc
purul
respiratori
secret
andor
posit
result
respiratori
cultur
blood
cultur
andor
posit
urinari
antigen
test
legionella
pneumophila
streptococcu
pneumonia
exclud
analysi
figur
children
year
old
one
patient
older
year
old
also
exclud
order
make
group
compar
age
pregnant
women
also
exclud
avoid
confus
factor
analysi
immun
respons
viru
sinc
pregnanc
induc
physiolog
chang
immun
system
figur
inform
consent
obtain
directli
patient
legal
repres
also
healthi
control
enrol
approv
studi
protocol
scientif
ethic
aspect
obtain
scientif
committe
clinic
research
coordin
center
hospit
clinico
universitario
de
valladolid
spain
sampl
collect
transport
blood
sampl
collect
experienc
nurs
singl
serum
sampl
obtain
patient
control
serum
sampl
obtain
proper
centrifug
sent
refriger
nation
influenza
center
valladolid
spain
store
immun
mediat
profil
haemagglutin
inhibit
activ
hi
viral
load
evalu
nasopharyng
swab
preserv
viru
transport
medium
sent
world
health
organ
associ
nation
influenza
center
valladolid
majadahonda
barcelona
spain
viral
diagnosi
purpos
viral
rna
nasopharyng
swab
obtain
use
automat
extractor
biomerieux
marci
letoil
franc
roch
basel
switzerland
viral
presenc
assess
real
time
pcr
base
method
use
reagent
provid
free
charg
center
diseas
control
cdc
atlanta
usa
purchas
roch
basel
switzerland
detect
set
plate
termocycl
roch
basel
switzerland
appli
biosystem
foster
citi
ca
usa
viral
load
measur
viral
load
measur
compar
group
real
time
revers
transcript
pcr
rna
extract
serum
briefli
extern
curv
obtain
use
serial
dilut
human
rna
extract
cultur
monocyt
leukemia
cell
human
gene
gapdh
employ
report
gene
neuraminidas
gene
amplifi
qrtpcr
serum
sampl
cross
point
extrapol
extern
curv
analysi
sampl
standard
curv
conduct
use
fast
softwar
appli
result
given
rel
comparison
pg
sequenc
primer
pair
revers
neuraminidas
forward
revers
serum
chemokin
cytokin
level
evalu
use
multiplex
biorad
plex
assay
hercul
ca
usa
system
allow
quantit
measur
differ
chemokin
cytokin
growthfactor
immun
mediat
consum
small
amount
biolog
materi
furthermor
system
good
represent
analyt
inflammatori
cytokin
antiinflammatori
cytokin
cytokin
cytokin
cytokin
chemokin
allow
test
differenti
level
regulatori
cytokin
serum
sever
mild
patient
addit
interferon
adiponectin
leptin
measur
use
enzymelink
inmuno
adsorb
assay
elisa
r
system
minneapoli
mn
usa
hi
assay
perform
aliquot
sampl
univers
health
network
uhn
toronto
ontario
canada
sera
treat
receptordestroy
enzym
rde
v
cholera
dilut
one
part
serum
three
part
enzym
incub
overnight
water
bath
enzym
inactiv
incub
follow
addit
six
part
physiolog
salin
final
dilut
hi
assay
perform
vbottom
microtit
plate
corn
costar
co
cambridg
usa
turkey
erythrocyt
previous
describ
use
inactiv
pandem
influenza
antigen
data
analysi
perform
use
spss
comparison
group
perform
use
non
parametr
umann
whitney
test
data
display
mean
standard
deviat
clinic
laboratori
paramet
median
interquartil
rank
data
sampl
collect
time
immun
mediat
level
associ
variabl
determin
calcul
spearman
correl
coeffici
r
data
shown
r
p
valu
signific
fix
p
valu
patient
show
symptom
acut
respiratori
viral
infect
diseas
onset
frequent
initi
symptom
patient
group
critic
hospit
non
critic
outpati
fever
cough
headach
tired
myalgia
hospit
patient
show
dyspnoea
initi
symptom
case
develop
respiratori
insuffici
time
hospit
admiss
dyspnoea
andor
hypoxemia
defin
satur
breath
least
two
liter
oxygen
ten
patient
requir
admiss
intens
care
unit
icu
due
respiratori
situat
remain
admit
differ
special
hospit
servic
outpati
difficulti
respiratori
function
show
respiratori
rate
sex
composit
critic
non
critic
hospit
patient
patient
male
n
femal
n
fiftythre
percent
outpati
male
femal
n
respect
tabl
averag
age
follow
hospit
patient
outpati
healthi
control
critic
patient
slightli
older
hospit
patient
tabl
seven
patient
critic
ill
four
sever
patient
non
critic
ill
show
previou
patholog
tabl
ten
critic
patient
sever
non
critic
patient
show
patholog
chest
xray
within
hour
onset
symptom
tabl
outpati
receiv
antipyret
paracetamol
sampl
collect
none
receiv
oseltamivir
one
hundr
percent
hospit
patient
critic
non
critic
receiv
oseltamivir
time
sampl
collect
tabl
lymphopenia
common
find
critic
patient
mean
sd
ldh
level
increas
normal
level
hospit
patient
mostli
critic
ill
tabl
furthermor
critic
patient
also
show
high
level
cpk
got
gpt
glucos
venou
blood
tabl
critic
patient
stay
longer
hospit
hospit
patient
tabl
three
critic
patient
ultim
die
five
day
onset
due
hypoxemia
septic
shock
day
onset
refractori
hypoxemia
complic
system
candidiasi
third
day
support
therapi
multiorgan
failur
hi
activ
present
serum
two
critic
ill
patient
year
old
titr
respect
one
outpati
titr
serum
three
patient
show
hi
show
also
abil
block
viral
replic
assess
microneutr
assay
data
shown
data
support
notion
time
sampl
vast
major
patient
yet
produc
tabl
clinic
laboratori
characterist
patient
hospit
non
critic
ill
n
antibodi
earli
stage
diseas
viru
induc
mild
sever
patient
system
elev
three
chemokin
shown
express
earli
viral
infect
differ
level
mediat
data
immun
mediat
profil
shown
figur
addit
file
level
higher
hospit
patient
outpati
control
p
behav
similar
way
critic
noncrit
hospit
patient
show
higher
level
control
sever
non
critic
patient
show
signific
higher
level
mild
hand
increas
exclus
critic
patient
addit
show
highest
level
compar
group
determin
system
viral
load
play
role
chemokin
cytokin
express
level
evalu
serum
level
fiftyseven
percent
critic
patient
hospit
non
critic
patient
mild
patient
show
posit
viru
serum
posit
viru
serum
found
differ
viral
load
critic
patient
hospit
non
critic
ill
mild
outpati
figur
found
significantli
higher
level
hospit
patient
neg
viru
serum
compar
viru
serum
data
shown
similarli
invers
correl
found
viral
load
patient
requir
hospit
admiss
figur
mediat
level
correl
clinic
paramet
signific
invers
associ
found
hospit
patient
figur
exclus
critic
patient
group
invers
correl
non
critic
ill
hospit
patient
group
neg
associ
observ
first
attempt
understand
role
host
immun
respons
play
evolut
sever
mild
diseas
assess
system
level
chemokin
cytokin
sera
hospit
outpati
consist
previou
studi
earli
elev
express
sar
cov
rsv
infect
patient
found
present
studi
elev
express
chemokin
sever
patient
critic
non
critic
mild
patient
earli
express
chemokin
patient
like
indic
innat
antivir
host
respons
one
intrigu
observ
present
studi
dramat
increas
mediat
stimul
respons
one
sever
patient
figur
adapt
immun
import
respons
intracellular
microb
virus
immun
particip
clear
pathogen
host
defens
reaction
involv
also
tissu
inflamm
sever
autoimmun
diseas
allerg
diseas
asthma
increas
critic
non
critic
hospit
patient
compar
mild
one
indic
constitut
hallmark
sever
diseas
promot
antivir
immun
also
respiratori
tract
inflamm
recruit
neutrophil
mononuclear
cell
site
infect
cytokin
induc
differenti
cell
show
immunomodulatori
properti
attenu
cytokin
product
known
antiinflammatori
cytokin
murin
model
mckinstri
et
alrev
inhibit
develop
respons
influenza
infect
correl
compromis
protect
increas
hospit
patient
control
indic
also
parallel
sever
diseas
significantli
higher
level
sever
non
critic
patient
compar
mild
differ
found
critic
one
could
reflect
benefici
role
cytokin
particular
subset
patient
patient
die
five
day
diseas
onset
show
high
viral
load
undetect
level
serum
could
reflect
protect
role
sever
patient
constitut
hallmark
critic
ill
studi
three
cytokin
also
mediat
antivir
proinflammatori
respons
potent
regul
switch
immun
respons
induct
regulatori
cell
pathogen
cell
vivo
promot
cell
homeostat
prolifer
respons
infect
play
key
role
switch
innat
adapt
immun
level
immun
mediat
four
group
level
immun
mediat
four
group
signific
differ
control
level
p
high
level
relat
mediat
could
support
hypothesi
inflammatori
respons
origin
sever
respiratori
diseas
caus
infect
altern
increas
cytokin
may
reflect
vigor
antivir
host
respons
necessari
clearanc
viru
sever
lower
respiratori
infect
abil
influenza
viru
induc
product
chemotact
rant
proinflammatori
relat
mediat
well
know
previou
report
season
influenza
first
report
evidenc
respons
signatur
sever
influenza
diseas
human
sinc
immunomodulatori
drug
shown
downmodul
activ
result
obtain
support
develop
studi
anim
model
aim
clarifi
role
mediat
pathogenesi
acut
respiratori
diseas
show
sever
infect
patient
analysi
immun
mediat
involv
host
respons
viru
mild
sever
case
reveal
cytokin
respons
earli
distinct
hallmark
sever
respiratori
compromis
follow
infect
exact
role
mediat
evolut
mild
sever
diseas
merit
investig
detriment
benefici
role
cytokin
play
sever
ill
influenc
condit
autoimmun
diseas
defici
one
hiv
infect
diseas
outcom
also
explor
furthermor
impact
regulatori
cytokin
elev
sever
diseas
evolut
host
immun
respons
infect
may
repres
altern
therapeut
control
sever
ill
correl
studi
correl
studi
left
right
correl
level
viral
load
serum
correl
level
viral
load
serum
correl
serum
level
great
major
infect
caus
new
influenza
pandem
viru
mild
selflimit
natur
nevertheless
small
percentag
patient
develop
sever
respiratori
diseas
analysi
immun
mediat
involv
host
respons
viru
along
evalu
humor
respons
mild
sever
case
may
help
understand
pathogen
event
lead
poor
outcom
earli
respons
viru
hospit
outpati
character
express
chemokin
also
observ
respons
sar
cov
rsv
previou
literatur
describ
correspond
innat
antivir
respons
patient
develop
respiratori
compromis
first
day
follow
infect
typic
show
hypercytokinemia
compar
mild
patient
healthi
control
cytokin
profil
previous
report
particip
antivir
proinflammatori
respons
increas
system
level
constitut
hallmark
critic
ill
mediat
known
promot
develop
adapt
respons
also
proinflammatori
one
viral
infect
find
constitut
major
avenu
guid
design
work
studi
benefici
detriment
role
respons
diseas
follow
addit
file
avail
onlin
predomin
cytokin
profil
parallel
earli
diseas
clinic
sever
predomin
cytokin
profil
parallel
earli
diseas
clinic
sever
